Epibiologics Appoints Ann Lee-Karlon As Chief Executive Officer And President, Extends Series A Financing To Over $70 Million
Epibiologics Appoints Ann Lee-Karlon As Chief Executive Officer And President, Extends Series A Financing To Over $70 Million
07/20/23, 12:10 PM
Location
san mateoIndustry
biotechnology
Round Type
series a
Investors
Gv, Vivo Capital, Polaris Partners, Mubadala Capital, Codon Capital, Taiho Ventures, Digitalis Ventures
EpiBiologics, a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets, announced today that Ann Lee-Karlon, Ph.D., will join as Chief Executive Officer, President, and member of the Board of Directors. Dr. Lee-Karlon will focus on expanding EpiBiologics’ proprietary EpiTAC platform, establishing value-driven collaborations, and building the company’s pipeline of bispecific antibody protein degrader therapeutics.
Company Info
Location
1900 alameda de las pulgas
san mateo, california, united states
Additional Info
EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas.